Servier

189 articles about Servier

• Servier And Pfizer Announce FDA Clearance Of IND Application For UCART19 In Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

  3/9/2017

• Servier Release: Appoints MaSTherCell For The Development Of Its CAR-T Cell Therapy Manufacturing Platform

  1/23/2017

• Servier Release: Company Appoints MaSTherCell For The Development Of Its CAR-T Cell Therapy Manufacturing Platform

  1/18/2017

• Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier

  1/6/2017

• OSE Immunotherapeutics Inks Key Agreement With Paris-Based Servier for Effi-7; OSE to Receive Up to €272 Million and Upfront €10.25 Million

  12/28/2016

• Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure

  9/1/2016

• Vernalis PLC Achieves A Milestone In Its Oncology Collaboration With Servier

  7/19/2016

• San Diego's Sorrento Forges €735 Million Immuno-Onco Tie-Up with Servier

  7/12/2016

• Servier Release: Patients With Advanced Metastatic Colorectal Cancer In Europe Now Have A New Treatment Option As LONSURF(Trifluridine/Tipiracil) Receives EU Approval

  4/27/2016

• Servier Receives Positive CHMP Opinion For LONSURF (Trifluridine/Tipiracil) For Refractory Metastatic Colorectal Cancer

  2/26/2016

• Spectrum Pharma Signs A Strategic Partnership With Servier Canada

  1/11/2016

• Cellectis Announces Conference Call To Discuss UCART19 Development Collaboration With Pfizer And Servier

  12/4/2015

• Servier Slashes 610 Jobs in Company Reorganization

  12/1/2015

• Galapagos Initiates Phase 1 First-In-Human Study With GLPG1972, Receives €3.5 Million Milestone From Servier

  11/20/2015

• Servier Exercises Exclusive Worldwide Licensing Option With Cellectis For UCART19, An Allogeneic CAR-T Cell Therapy For Hematological Malignancies

  11/19/2015

• Pfizer, Servier Snap Up Right to Cellectis' Blood Cancer Therapy in $338 Million+ Deal

  11/19/2015

• Servier Walks Away from a $450 Million Cancer Deal with MacroGenics, Inc.

  10/28/2015

• VECT-HORUS Announces The Signing Of A Scientific Collaboration Agreement With Servier

  6/19/2015

• Servier, Taiho Pharma Strike $130 Million+ Cancer Pact

  6/15/2015

• Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy

  4/1/2015